ISA Pharmaceuticals Archives - Page 3 of 3

ISA Pharmaceuticals to present at the Virtual 6th Solebury Trout Summer 2020 Private Company Showcase

06 Aug 2020

ISA Pharmaceuticals to present at the 33rd International Papillomavirus Conference & Basic Science

20 Jul 2020

ISA Pharmaceuticals will move to BioPartner 5

10 Jul 2020

The deal is sealed. This week contracts were signed to make it official: ISA will move to the new BioPartner 5 building as soon as it is ready.

Over the past period we have been expanding and further growth is anticipated. We’re on a roll and rapidly outgrowing our current offices and lab space. Our collaboration with Regeneron for our lead asset ISA101b is booming and we are about to enter the clinic with other therapeutics in our pipeline.

To accommodate future expansion – in line with an aggressive growth strategy – we will move to a new building and double in

ISA Pharmaceuticals receives US Orphan-Drug Designation for ISA101b in HPV16-positive Cervical Cancer

01 Jul 2020

Leiden, The Netherlands, 01 July 2020 — ISA Pharmaceuticals B.V., today announced that it received Orphan Drug Designation from the Food and Drug Administration (FDA) in the USA for its lead product ISA101b for treatment of Human Papilloma Virus type 16 (HPV16)-positive cervical cancer.

According to the latest statistics of the Centers for Disease Control and Prevention, HPV causes more than 34,000 cases of cancer in the United States each year. Cervical cancer is the most common HPV-associated cancer in women, with HPV16 being responsible for approximately 50% of cases. HPV16-positive cervical cancer is the number 2 cause of cancer for women in

ISA Pharmaceuticals Strengthens Strategic Immuno-Oncology Collaboration with Regeneron

17 Jun 2020

Leiden, The Netherlands, June 17, 2020, — ISA Pharmaceuticals B.V., a private clinical-stage immunotherapy company, today announced plans to initiate a potentially pivotal clinical trial for the combination of ISA101b and Libtayo® (cemiplimab) in oropharyngeal cancer, a type of head-and-neck cancer, under its strategic immuno-oncology collaboration with Regeneron. In addition, Regeneron will increase its equity stake in ISA Pharmaceuticals.

The new oropharyngeal cancer trial is
the third trial planned under the clinical collaboration between ISA Pharmaceuticals
and Regeneron. ISA101b, an immunotherapy targeting human papillomavirus type 16
(HPV16), is currently in a Phase 2 clinical trial for first- and second-line
HPV16-positive head-and-neck cancer in combination with

Vaccine + chemo activate immune response against cervical cancer

09 Apr 2020

Vaccine-Chemo Combo Shows Promise in Treating Advanced, HPV-Associated Cervical Cancer

30 Mar 2020

Blog by Arthur N. Brodsky, PhD, published on Cancerresearch.org on 27 March 2020. Click here to access the original article.

Just weeks after International Human Papilloma Virus (HPV) Awareness
Day, new results
from two long-time Cancer Research Institute (CRI) scientists highlighted the
promise of immunotherapy against HPV-associated cervical cancer.

In a phase 1/2 study, women with advanced, recurrent, or
metastatic cervical cancer were treated with the combination of an
HPV-targeting vaccine and standard-of-care chemotherapy. Of 72 evaluable
patients, 43 percent had their tumors shrink.

Led by Cornelis J.
M. Melief, M.D, Ph.D., and Sjoerd H. van der Burg, Ph.D.,
this clinical breakthrough was the latest fruit borne by the duo, both of
whom have been supported

ISA Pharmaceuticals announces CervISA publication

19 Mar 2020

Synergy between Synthetic Long Peptides (SLP®) immunotherapeutics and standard chemotherapy in late stage cancer including meaningful survival improvements in SLP immune responders

Leiden, The Netherlands, 19 March 2020 — ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company, announces publication of its phase 2, CervISA study in the peer-reviewed journal “Science Translational Medicine”. The paper titled ‘Strong vaccine responses during chemotherapy are associated with prolonged survival’ can be found here.

The CervISA study was an open label, phase 2 study in patients with late stage HPV16 positive cervical cancer. Seventy-seven patients were treated with ISA Pharma’s lead product, ISA101b, an HPV16-specific immunotherapeutic

ISA Pharmaceuticals B.V. receives EUR 20m loan from European Investment Bank

13 Oct 2019

Financing
to boost late-stage development of novel therapy to treat life-threatening, virus-induced
cancersLoan supported
by the “InnovFin
–
EU-finance for innovators”
programme

The European Investment Bank and ISA Pharmaceuticals have signed a EUR 20 million loan agreement to support the development of ISA’s therapy for cancers caused by the Human Papillomavirus type 16 (HPV16).

Persistent
HPV16 infection can cause cervical, head & neck and anogenital cancers.
These cancers can be severe and life-threatening, with low overall survival
rates of advanced stages. Cervical cancer is the 2nd most common
cancer in women aged 15 to 44 years in Europe, with HPV16 causing over 35,000
new cases and 15,000 deaths each year. The

ISA Pharmaceuticals Strengthens its Supervisory Board with the Addition of Dr. Markwin Velders

02 Sep 2019

– Seasoned biotech expert to support corporate development

Leiden, The Netherlands, September 02, 2019 – ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company focusing on rationally designed immunotherapeutics against cancer and persistent viral infections, today announced the addition of Dr. Markwin Velders to its Supervisory Board. Dr. Velders brings many years of experience in the biotech industry and currently holds a position as VP Operations and Managing Director at Kite Pharma EU, a leading company in the field of immuno-oncology and cell therapy.

“As we are entering the final stages of clinical development for our lead product ISA101b, we are happy to further